Teva and Fosun Pharma Forge Strategic Partnership to Develop and Commercialize Innovative Anti-PD1-IL2 Therapy (TEV-56278) in Immuno-Oncology Teva Pharmaceutical Industries Ltd.and Shanghai Fosun Pharmaceutical (Group) Co., Ltd.today announced a significant strategic partnership for the development and eventual commercial delivery of…
BioMarin Boosts Enzyme Therapy Business with Inozyme Acquisition BioMarin Pharmaceutical and Inozyme Pharma today announced that BioMarin has entered into a definitive agreement to acquire Inozyme for $4.00 per share in an all-cash transaction valued at approximately $270 million in…
WuXi AppTec Recognized Among Top 10 “Most Honored Companies” in Extel 2025 Asia Executive Team Rankings, Continuing its Global Leadership in Innovation and Drug Discovery Services WuXi AppTec, a leading global company that provides a broad portfolio of research and…
Bristol Myers Squibb Presents Positive Transcend FL Data Highlighting Durable Responses with Breyanzi in Relapsed or Refractory Marginal Zone Lymphoma Bristol Myers Squibb today announced the first disclosure of the primary analysis results from the marginal zone lymphoma (MZL) cohort…
Roche Advances Prasinezumab into Phase III Development for Early-Stage Parkinson’s Disease Roche today announced its decision to move forward with Phase III clinical development of prasinezumab — its investigational, humanized monoclonal antibody designed to target and reduce the accumulation of…
Lilly to Expand Access to Zepbound: All Approved Doses Now Available in Vials Through LillyDirect’s Self-Pay Pharmacy Solutions Eli Lilly and Company today made a significant announcement aimed at improving patient access to its obesity treatment Zepbound (tirzepatide). The company…
Intellia Therapeutics Reports Positive 3-Year Phase 1 Data for Lonvo-z in Hereditary Angioedema — Highlights Durable Benefit and Safety Intellia Therapeutics, a leading clinical-stage genome-editing biotechnology company, today presented updated and extensive follow-up data from the Phase 1 portion of…
Sarepta Takes Action to Strengthen ELEVIDYS Safety Measures in Non-Ambulatory Duchenne Patients Sarepta Therapeutic a leading innovator in precision genetic medicine for rare disorders, today provided a significant safety update for ELEVIDYS (delandistrogene moxeparvovec-rokl). ELEVIDYS is currently the only U.S.…
QIAGEN and Incyte Forge Global Collaboration to Develop Companion Diagnostic Panel for Patients With Mutant CALR-Positive Myeloproliferative Neoplasms QIAGEN N.V. and Incyte today announced a significant new collaboration aimed at improving the standard of care for patients battling myeloproliferative neoplasms…
Genmab Presents Positive Epcoritamab Combination Data in Relapsed or Refractory DLBCL Eligible for Autologous Stem Cell Transplantation Genmab A/S today shared new and highly promising data from its Phase 1b/2 EPCORE® NHL-2 trial (Arm 10, NCT04663347) evaluating its T-cell-engaging bispecific…
Sanofi and Regeneron’s Dupixent Shows Superiority over Xolair in First-Ever Head-to-Head Phase 4 Study in Patients with Severe Chronic Rhinosinusitis with Nasal Polyps and Co-existing Asthma Sanofi and Regeneron Pharmaceuticals, Inc. today presented new and significant data demonstrating the superiority…
Roche Suspends Elevidys Dosing in Non-Ambulatory DMD Patients Amid Safety Concerns Roche today announced a significant update to its dosing guidelines for Elevidys™ (delandistrogene moxeparvovec), following a careful reassessment of its benefit-risk profile in non-ambulatory patients with Duchenne muscular dystrophy…